Enabling access to Cortellis intelligence helps to accelerate innovation in Australia’s leading biomedical precinct.
Clarivate Analytics has signed an agreement to provide drug discovery intelligence across the Melbourne Biomedical Precinct (MBP). Under the agreement, The University of Melbourne, Monash University, BioCurate and The Walter Eliza Hall Institute of Medical Research will have enterprise-wide access to Cortellis drug discovery intelligence to support their strategic research practices from early science through drug discovery. Cortellis is a suite of life science solutions from Clarivate Analytics that inform decision-making across the drug/device development and commercialization spectrum.
Through Cortellis, MBP precinct members will be able to use key scientific information and insights to prioritize drug development candidates, benchmark other companies, and assess the competitive landscape early in the research process.
The data is available via a single point of access to Cortellis, enabling a fast, efficient and comprehensive view of an indication and its potential.
Scientific data included in Cortellis spans more than 500,000 drugs and biologics, 6,600 targets, 41,000 biomarkers, 2.9 million biomarker uses, 2.4 million pharmacology data points, 99,000 experimental models and 430,000 patents. The solution was developed by scientists for scientists, and features intelligence that has been manually curated and validated by Clarivate’s content operations teams.
The Melbourne Biomedical Precinct is Australia’s leading biomedical precinct. It is made up of over 40 hospitals, research, teaching and biotechnology organizations in Melbourne, the second largest city in Australia. [APBN]